No effect of the turmeric root phenol curcumin on prednisolone-induced gluco-metabolic perturbations in men with overweight or obesity
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
No effect of the turmeric root phenol curcumin on prednisolone-induced gluco-metabolic perturbations in men with overweight or obesity. / Hellmann, Pernille H; Bagger, Jonatan I.; Carlander, Katrine R.; Hansen, Katrine B.; Forman, Julie L.; Størling, Joachim; Chabanova, Elizaveta; Holst, Jens Juul; Vilsbøll, Tina; Knop, Filip K.
In: Endocrine Connections, Vol. 12, No. 4, e220334, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - No effect of the turmeric root phenol curcumin on prednisolone-induced gluco-metabolic perturbations in men with overweight or obesity
AU - Hellmann, Pernille H
AU - Bagger, Jonatan I.
AU - Carlander, Katrine R.
AU - Hansen, Katrine B.
AU - Forman, Julie L.
AU - Størling, Joachim
AU - Chabanova, Elizaveta
AU - Holst, Jens Juul
AU - Vilsbøll, Tina
AU - Knop, Filip K
PY - 2023
Y1 - 2023
N2 - OBJECTIVES: Preclinically, curcumin has been shown to protect against glucocorticoid-induced insulin resistance. We evaluated the effect of curcumin administered with prednisolone in healthy overweight or obese men.METHODS: In a double-blind, parallel-group trial, 24 overweight/obese non-diabetic men were randomised to one of three intervention groups A) prednisolone placebo+curcumin placebo, B) prednisolone (50 mg/day)+curcumin placebo or C) prednisolone and curcumin (400 mg/day). Curcumin or curcumin placebo treatment started one day prior to 10-day prednisolone or prednisolone placebo treatment. The primary endpoint was change in prednisolone-induced insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA2-IR). Other endpoints included anthropometric measurements, magnetic resonance spectroscopy-assessed hepatic fat content, blood pressure, circulating metabolic markers and continuous glucose monitoring measures.RESULTS: Baseline characteristics (mean ± SD): age 44.2 ± 13.7 years, body mass index 30.1 ± 3.5 kg/m2, glycated haemoglobin A1c 33.3 ± 3.2 mmol/mol, HOMA2-IR 1.10 ± 0.45 and fasting plasma glucose 5.2 ± 0.4 mmol/L. Prednisolone significantly increased HOMA2-IR (estimated treatment difference 0.36 [95% CI 0.16; 0.57]). Co-treatment with curcumin had no effect on HOMA2-IR (estimated treatment difference 0.08 [95% CI -0.13; 0.39]). Prednisolone increased glycated haemoglobin A1c, insulin, C-peptide, glucagon, blood pressure, mean interstitial glucose, time spent in hyperglycaemia and glucose variability, but no protective effect of curcumin on any of these measures was observed.CONCLUSIONS: In this double-blind, placebo-controlled parallel-group study involving 24 overweight or obese men randomised to one of three treatment arms, curcumin treatment had no protective effect on prednisolone-induced insulin resistance or other gluco-metabolic perturbations.
AB - OBJECTIVES: Preclinically, curcumin has been shown to protect against glucocorticoid-induced insulin resistance. We evaluated the effect of curcumin administered with prednisolone in healthy overweight or obese men.METHODS: In a double-blind, parallel-group trial, 24 overweight/obese non-diabetic men were randomised to one of three intervention groups A) prednisolone placebo+curcumin placebo, B) prednisolone (50 mg/day)+curcumin placebo or C) prednisolone and curcumin (400 mg/day). Curcumin or curcumin placebo treatment started one day prior to 10-day prednisolone or prednisolone placebo treatment. The primary endpoint was change in prednisolone-induced insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA2-IR). Other endpoints included anthropometric measurements, magnetic resonance spectroscopy-assessed hepatic fat content, blood pressure, circulating metabolic markers and continuous glucose monitoring measures.RESULTS: Baseline characteristics (mean ± SD): age 44.2 ± 13.7 years, body mass index 30.1 ± 3.5 kg/m2, glycated haemoglobin A1c 33.3 ± 3.2 mmol/mol, HOMA2-IR 1.10 ± 0.45 and fasting plasma glucose 5.2 ± 0.4 mmol/L. Prednisolone significantly increased HOMA2-IR (estimated treatment difference 0.36 [95% CI 0.16; 0.57]). Co-treatment with curcumin had no effect on HOMA2-IR (estimated treatment difference 0.08 [95% CI -0.13; 0.39]). Prednisolone increased glycated haemoglobin A1c, insulin, C-peptide, glucagon, blood pressure, mean interstitial glucose, time spent in hyperglycaemia and glucose variability, but no protective effect of curcumin on any of these measures was observed.CONCLUSIONS: In this double-blind, placebo-controlled parallel-group study involving 24 overweight or obese men randomised to one of three treatment arms, curcumin treatment had no protective effect on prednisolone-induced insulin resistance or other gluco-metabolic perturbations.
U2 - 10.1530/EC-22-0334
DO - 10.1530/EC-22-0334
M3 - Journal article
C2 - 36800259
VL - 12
JO - Endocrine Connections
JF - Endocrine Connections
SN - 2049-3614
IS - 4
M1 - e220334
ER -
ID: 340116991